Demographic data of patients with GO
| Variable | All | Mild GO (control) | Severe GO (case) | P value |
| Sex (female:male) | 62:38 | 24:8 | 38:30 | 0.07 |
| Age | 48.8±12.2 | 47.38±14.4 | 49.41±11.2 | 0.44 |
| Exophthalmos (mm) | ||||
| Right eye | 18.1±3.5 | 17.2±3.1 | 18.6±3.6 | 0.04 |
| Left eye | 18.8±4.7 | 17.3±3.2 | 19.5±5.2 | 0.02 |
| Euthyroid state (current status) | 69 | 26 | 43 | 0.07 |
| Clinical activity score (minimum– maximum) | 0.4±0.9 (0–6) | 0.2±0.6 (0–2) | 0.4±1.1 (0–6) | 0.19 |
| Smoking | 9 | 1 | 8 | 0.27 |
| Diabetes | 13 | 2 | 11 | 0.22 |
| Treatment for GO | ||||
| Intravenous methylprednisolone | 19 | 4 | 15 | 0.26 |
| Oral steroid | 12 | 1 | 11 | 0.10 |
| Orbitotomy | 20 | 5 | 15 | 0.45 |
| Treatment for thyroid disease | ||||
| Antithyroid medication | 54 | 16 | 38 | 0.58 |
| Radioiodine | 15 | 5 | 10 | 1.0 |
| Thyroidectomy | 5 | 1 | 4 | 1.0 |
| Thyroxine | 18 | 7 | 11 | 0.49 |
GO, Graves’ orbitopathy.;